Serial entrepreneurs, scientists and business leaders committed to innovation

John A. Dawson, CBE, is a highly experienced and globally respected figure in the healthcare sector. Most recently, he was Chief Executive Officer of Oxford Biomedica where, during his 13-year tenure, the business grew into a global market leader in viral vector technologies for cell and gene therapy, and delivered multiple high value partnerships. The company successfully manufactured the life-saving Oxford / AstraZeneca COVID-19 vaccine in early 2021.

Susan Dexter is Chief Technical Officer / CMC Supply Chain and Non-Clinical Lead at Sonnet BioTherapeutics, Inc., managing all activities related to cell line development, process development and cGMP manufacturing, non-clinical studies and clinical supply chain. She has over thirty-five years of experience in biotechnology sciences and business development including drug development and in the CDMO arena for biological products.

David Enloe brings nearly three decades of executive leadership experience in biotechnology, clinical drug development, and GMP manufacturing. David is currently President and CEO of Societal CDMO, a company with a focus on novel formulation development and clinical through commercial scale manufacturing of pharmaceutical products.